A Site Initiation Visit (SIV) is the formal start-up appointment for a clinical investigational site shortly before recruitment begins, during which the sponsor or CRO trains the site study team in all essential trial requirements and documents site readiness.
In German-speaking countries, the term is sometimes also referred to as an “initiation visit” or “initiation meeting”. It is a central element of trial organisation and connects the Study Start-up phase with operational conduct at the site. The SIV is therefore not merely a “kick-off” but a documented quality step with clear acceptance criteria.
Objectives and typical procedure
The SIV is intended to ensure that the investigational site is organisationally and technically ready to conduct the trial in accordance with the clinical study protocol and Good Clinical Practice (GCP). Typical elements include a structured agenda, protocol training, and a documented close-out with open items and responsibilities.
- Presentation of the trial and clarification of roles (investigator, study coordination, pharmacy, laboratory, radiology where applicable) including deputisation arrangements.
- Review of inclusion and exclusion criteria, recruitment, screening, the visit schedule, and deviation management for protocol deviations.
- Training on safety processes: capturing, assessing and reporting adverse events, serious adverse events, and safety follow-up letters.
- Training on data processes: Electronic Data Capture, Electronic Case Report Form, query management, data corrections, and handling of the audit trail.
In the EU, it is also often checked whether essential documents in the Trial Master File and Investigator Site File are complete and whether approvals (Ethics Committee, competent authority, contracts, proof of insurance) are documented consistently. Depending on the trial, requirements for randomisation, emergency unblinding and handling of amendments are also explained.
Content: training, documentation and systems
The substantive core of an SIV is target-group-appropriate training. This includes protocol training, safety training (pharmacovigilance processes), and system training. The practical handling of trial-specific procedures is often practised, for example the documentation of consent processes (Informed Consent), the use of eConsent, or the logistics of investigational medicinal products.
From a monitoring perspective, expectations regarding Source Data Verification, Source Data Review and local archiving in the Investigator Site File are explained during the SIV. It is essential that the site understands the definition of source data, that corrections are traceable, and that responsibilities for data release are clearly regulated. Equally important are clear communication channels, for example when a monitoring visit is planned and how quickly queries should be answered in everyday practice.
For complex trials, a process walkthrough is often also included: from the first patient contact through screening and randomisation to the reporting of safety events. Such end-to-end run-throughs prevent later misunderstandings that would otherwise only become apparent at the first monitoring visit.
Prerequisites and site readiness criteria
An SIV is only meaningful once key prerequisites have been met. These include a completed Study Start-up phase with activated contracts, trained staff and verified infrastructure. Many sponsors use standardised checklists that, in addition to training, also cover technical and organisational aspects: access to systems, laboratory transport, availability of equipment, data protection processes, and the naming of deputies.
In practice, misunderstandings often arise here: a site may be technically suitable but not yet operationally ready to start, for example because the local pharmacy has not received final documents on investigational medicinal product labelling, recruitment pathways are not realistic, or responsibilities within the team have not been clearly clarified. A cleanly documented SIV reduces subsequent rework and prevents unnecessary monitoring follow-up letters and late corrections shortly before the First Patient First Visit.
Relevance for clinical trials
The SIV is a quality and risk-minimisation instrument. It creates a shared understanding of the trial across all sites, which is particularly important in multicentre trials. For the sponsor and CRO, the SIV is also an operational milestone: only after documented initiation is the site classed as “active” in many projects and permitted to begin screening and recruitment.
Full-service CROs such as mediconomics typically provide support through standardised training materials, role-based training concepts and traceable documentation (attendance lists, agenda, training records, open items). This facilitates audits and inspections and improves the evidence provided to authorities, as it demonstrates that the site was adequately prepared.
Frequently Asked Questions (FAQ)
Is a Site Initiation Visit mandatory?
A formal SIV is not explicitly required under every regulatory framework, but it is an established standard in GCP-compliant trials. What matters is that training, role clarification and start-up approval are documented and that the site can conduct the trial correctly.
When does an SIV take place and what is the difference from a Pre-study Visit?
The SIV typically takes place shortly before recruitment begins, once approvals are in place and systems are ready. A Pre-study Visit is more concerned with assessing feasibility and processes prior to the final selection or activation of a site.
Which documents should be available after the SIV?
Typical documents include the agenda, attendance list, training materials, evidence of training, and documented start-up approval including open items. In addition, essential documents in the Investigator Site File should be complete and up to date, including safety and data management processes.
Regulatory references
- ICH E6(R3) Good Clinical Practice: Requirements for training, roles, documentation and quality systems in the conduct of clinical trials.
- Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR): EU framework for the authorisation, conduct and oversight of clinical trials; requires robust documentation and compliance.
- EU GMP Guide (EudraLex, Vol. 4) Annex 13 (Investigational Medicinal Products): Relevant requirements for the labelling, release and handling of investigational medicinal products at investigational sites.